Cinclus Pharma Holding AB is a Swedish pharmaceutical company that focuses on developing clinical stage drug candidates for gastric acid related diseases. The company's drug candidate, linaprazan glurate, takes a new approach to provide improved management of GERD. Gastroesophageal reflux disease, or acid reflux, is a condition in which the content of the stomach regurgitates into the esophagus. The company was founded by pioneers in GERD treatment with extensive experience from Astra and Astra Zeneca. Christer Ahlberg has been the CEO of the company since 2021.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company